secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001193125-24-056839
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs appoints Dr. Clay Siegall and Dr. Kate Sasser to board of directors
--------------------------------------------------------------------------------

- Appointments effective March 1, 2024; board now includes two new independent directors.
- Dr. Siegall is CEO/Chairman of Immunome (IMNM) and former CEO/Chairman of Seagen (acquired by Pfizer).
- Dr. Sasser is Chief Scientific Officer of Tempus AI and previously led translational research at Genmab and J&J.
- Co. expects clinical updates for SL-172154 mid-2024 and plans late-stage/pivotal studies in multiple indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000119312524056839/0001193125-24-056839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000119312524056839/d806380d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-056839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer